selected publications
- Availability of Suitable Domestic Cord Blood Grafts for Adult Allograft Recipients With Hematologic Malignancies. Transplantation and cellular therapy. 2025 Academic Article GET IT
- US Geriatric Assessment Practices for Older Adults Undergoing Hematopoietic Cell Transplantation or Chimeric Antigen Receptor T Cell Therapy: An American Society for Transplantation and Cellular Therapy Physician Survey from the Aging Special Interest Group and Committee on Practice Guidelines. Transplantation and cellular therapy. 2025 Guideline GET IT
- Precision medicine results from equitable representation. Bone marrow transplantation. 2024 Academic Article GET IT
-
Safety and Toxicity Profiles of CAR T Cell Therapy in Non-Hodgkin Lymphoma: A Systematic Review and Meta-Analysis.
Clinical lymphoma, myeloma & leukemia.
2024
Review
GET IT
Times cited: 9 -
Deposition of complement components C5b-9 and MASP2 in tissues is not a feature of GVHD and may assist in discriminating GVHD from thrombotic microangiopathy following allogenic transplantation.
Bone marrow transplantation.
2023
Letter
GET IT
Times cited: 2 - Measurable residual disease after CAR T-cell therapy. Seminars in hematology. 2023 Review GET IT
-
Screening Chest CT Prior to Allogenic Hematopoietic Stem Cell Transplantation.
Transplantation and cellular therapy.
2023
Academic Article
GET IT
Times cited: 6 -
Wide variation in use and interpretation of gene mutation profiling panels among health care providers of patients with myelodysplastic syndromes: results of a large web-based survey.
Leukemia & lymphoma.
2020
Academic Article
GET IT
Times cited: 3 -
Getting personal with myelodysplastic syndromes: is now the right time?.
Expert review of hematology.
2019
Review
GET IT
Times cited: 9 -
The Rising Era of Immune Checkpoint Inhibitors in Myelodysplastic Syndromes.
Advances in hematology.
2018
Review
GET IT
Times cited: 16 -
Immunosuppressive therapy in myelodysplastic syndromes: a borrowed therapy in search of the right place.
Expert review of hematology.
2018
Review
GET IT
Times cited: 12 -
Fulminant Diabetes in a Patient with Advanced Melanoma on Nivolumab.
2018
GET IT
Times cited: 78